Basic Immunologic Study As a Foundation for Engineered Therapeutic Development

Overview

Journal Pharmacol Res Perspect

Date 2024 Jun 19

PMID 38894611

Authors

Sabrina DeStefano

Daphna Fertil

Mondreakest Faust

Kaitlyn Sadtler

Affiliations

Soon will be listed here.

Abstract

Bioengineering and drug delivery technologies play an important role in bridging the gap between basic scientific discovery and clinical application of therapeutics. To identify the optimal treatment, the most critical stage is to diagnose the problem. Often these two may occur simultaneously or in parallel, but in this review, we focus on bottom-up approaches in understanding basic immunologic phenomena to develop targeted therapeutics. This can be observed in several fields; here, we will focus on one of the original immunotherapy targets-cancer-and one of the more recent targets-regenerative medicine. By understanding how our immune system responds in processes such as malignancies, wound healing, and medical device implantation, we can isolate therapeutic targets for pharmacologic and bioengineered interventions.

Citing Articles

Basic immunologic study as a foundation for engineered therapeutic development.

DeStefano S, Fertil D, Faust M, Sadtler K Pharmacol Res Perspect. 2024; 12(4):e1168.

PMID: 38894611 PMC: 11187943. DOI: 10.1002/prp2.1168.

References

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

Bose S, Volpatti L, Thiono D, Yesilyurt V, McGladrigan C, Tang Y . A retrievable implant for the long-term encapsulation and survival of therapeutic xenogeneic cells. Nat Biomed Eng. 2020; 4(8):814-826. PMC: 8051527. DOI: 10.1038/s41551-020-0538-5. View

Klumper N, Ralser D, Zarbl R, Schlack K, Schrader A, Rehlinghaus M . promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. J Immunother Cancer. 2021; 9(8). PMC: 8395367. DOI: 10.1136/jitc-2021-002949. View

Corrales L, Glickman L, McWhirter S, Kanne D, Sivick K, Katibah G . Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015; 11(7):1018-30. PMC: 4440852. DOI: 10.1016/j.celrep.2015.04.031. View

Welch N, Winkler D, Thissen H . Antifibrotic strategies for medical devices. Adv Drug Deliv Rev. 2020; 167:109-120. DOI: 10.1016/j.addr.2020.06.008. View

Beanes S, Dang C, Soo C, Ting K . Skin repair and scar formation: the central role of TGF-beta. Expert Rev Mol Med. 2004; 5(8):1-22. DOI: 10.1017/S1462399403005817. View

Wang W, Zhao J, Hao C, Hu S, Chen C, Cao Y . The Development of Chiral Nanoparticles to Target NK Cells and CD8 T Cells for Cancer Immunotherapy. Adv Mater. 2022; 34(16):e2109354. DOI: 10.1002/adma.202109354. View

Sawaya A, Stone R, Brooks S, Pastar I, Jozic I, Hasneen K . Deregulated immune cell recruitment orchestrated by FOXM1 impairs human diabetic wound healing. Nat Commun. 2020; 11(1):4678. PMC: 7495445. DOI: 10.1038/s41467-020-18276-0. View

Burnet F . The concept of immunological surveillance. Prog Exp Tumor Res. 1970; 13:1-27. DOI: 10.1159/000386035. View

10.

Murray R, West Z, Cowin A, Farrugia B . Development and use of biomaterials as wound healing therapies. Burns Trauma. 2019; 7:2. PMC: 6346526. DOI: 10.1186/s41038-018-0139-7. View

11.

Wolf M, Dearth C, Ranallo C, LoPresti S, Carey L, Daly K . Macrophage polarization in response to ECM coated polypropylene mesh. Biomaterials. 2014; 35(25):6838-49. PMC: 4347831. DOI: 10.1016/j.biomaterials.2014.04.115. View

12.

Berebichez-Fridman R, Montero-Olvera P . Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review. Sultan Qaboos Univ Med J. 2019; 18(3):e264-e277. PMC: 6307657. DOI: 10.18295/squmj.2018.18.03.002. View

13.

Flood B, Higgs E, Li S, Luke J, Gajewski T . STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019; 290(1):24-38. PMC: 6814203. DOI: 10.1111/imr.12765. View

14.

Aldrak N, Alsaab S, Algethami A, Bhere D, Wakimoto H, Shah K . Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells. 2021; 10(6). PMC: 8235327. DOI: 10.3390/cells10061541. View

15.

Marin N, Krasnick B, Becker-Hapak M, Conant L, Goedegebuure S, Berrien-Elliott M . Memory-like Differentiation Enhances NK Cell Responses to Melanoma. Clin Cancer Res. 2021; 27(17):4859-4869. PMC: 8416927. DOI: 10.1158/1078-0432.CCR-21-0851. View

16.

Kroll A, Jiang Y, Zhou J, Holay M, Fang R, Zhang L . Biomimetic Nanoparticle Vaccines for Cancer Therapy. Adv Biosyst. 2019; 3(1):e1800219. PMC: 6855307. DOI: 10.1002/adbi.201800219. View

17.

Bliley J, Argenta A, Satish L, McLaughlin M, Dees A, Tompkins-Rhoades C . Administration of adipose-derived stem cells enhances vascularity, induces collagen deposition, and dermal adipogenesis in burn wounds. Burns. 2016; 42(6):1212-22. DOI: 10.1016/j.burns.2015.12.007. View

18.

Mirani B, Pagan E, Currie B, Siddiqui M, Hosseinzadeh R, Mostafalu P . An Advanced Multifunctional Hydrogel-Based Dressing for Wound Monitoring and Drug Delivery. Adv Healthc Mater. 2017; 6(19). PMC: 5845857. DOI: 10.1002/adhm.201700718. View

19.

Bluestone J, Buckner J, Fitch M, Gitelman S, Gupta S, Hellerstein M . Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015; 7(315):315ra189. PMC: 4729454. DOI: 10.1126/scitranslmed.aad4134. View

20.

Joshi V, Geary S, Salem A . Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2012; 15(1):85-94. PMC: 3535111. DOI: 10.1208/s12248-012-9418-6. View